Related Experiment Video
Updated: Apr 20, 2026

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis
Published on: March 20, 2026
Gastrointestinal cancer. Over the RAINBOW--renaissance in antiangiogenesis
1University Cancer Centre Leipzig (UCCL), University Hospital Leipzig, Liebigstrasse 20, D-04103 Leipzig, Germany.
Abstract:
The RAINBOW study has demonstrated that ramucirumab plus paclitaxel as second-line treatment for advanced-stage gastric cancer prolongs survival compared with paclitaxel alone. These data confirm that ramucirumab represents a new effective treatment option for gastric cancer. Nevertheless, new treatment options remain eagerly awaited in this disease with dismal outcomes.
Insights
Ramucirumab plus paclitaxel significantly improves survival for advanced gastric cancer patients receiving second-line therapy. This combination offers a new effective treatment option for this challenging disease.
Area of Science:
- Oncology
- Gastrointestinal Oncology
- Clinical Trials
Background:
- Advanced-stage gastric cancer has a poor prognosis.
- Limited effective second-line treatment options exist.
Purpose of the Study:
- To evaluate the efficacy of ramucirumab plus paclitaxel versus paclitaxel alone as second-line treatment for advanced gastric cancer.
Main Methods:
- The RAINBOW study was a randomized clinical trial.
- Patients received either ramucirumab plus paclitaxel or paclitaxel alone.
Main Results:
- Ramucirumab plus paclitaxel demonstrated a significant prolongation of survival compared to paclitaxel alone.
- This combination represents a new effective treatment option.
Conclusions:
- Ramucirumab plus paclitaxel is an effective second-line treatment for advanced gastric cancer.
- Further research for novel therapies is still needed due to the disease's poor outcomes.
More Related Videos
09:03Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells
Published on: November 23, 2014
07:59Evaluating the Angiogenetic Properties of Ovarian Cancer Stem-Like Cells using the Three-Dimensional Co-Culture System, NICO-1
Published on: December 5, 2020
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Targeted Cancer Therapies
Regulation of Angiogenesis and Blood Supply
Mechanism of Angiogenesis
Cancer
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists